Tuberculosis (TB) has now overtaken HIV as the deadliest infection worldwide, and we’re also losing ground to drug-resistant TB. Worse still: treatments for ‘multidrug-resistant tuberculosis’ (MDR-TB) are long, ineffective and have terrible side effects, including acute psychosis and permanent deafness.
After 50 years without new TB drugs, two were developed recently: bedaquiline and delamanid.
We’re partnering with leading medical organizations to get these drugs to patients in 15 countries, and revolutionise MDR-TB treatments. It’s called endTB.